Although no significant differences in melflufen activity were obtained for the remaining stratification factors, there was a clear trend for higher activity of melflufen in chemo-naïve patients, in patients responding to subsequent therapy, debut and primary AML.
← all excerpts
In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.
1
—
—